Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011;26 Suppl 3(0 3):331-6.
doi: 10.3233/JAD-2011-0021.

MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia

Affiliations
Randomized Controlled Trial

MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia

J W Ashford et al. J Alzheimers Dis. 2011.

Abstract

Objectives: Magnetic Resonance Spectroscopy (MRS) may provide a precise and reliable assessment of the extent and severity of neural tissue loss caused by various diseases. In particular, the N-Acetyl Aspartate (NAA) and Creatine (Cr) ratio has been found to be an indicator of the degree of neuronal loss in Alzheimer's disease (AD). Memantine is thought to benefit the AD brain by stabilizing the NMDA receptors on neurons in turn reducing excitotoxicity. Despite its effectiveness in treating moderate to severe AD, memantine has not had similar success in the treatment of mildly demented AD patients. The objective of this study was to test whether memantine would slow or prevent the loss of neurons in mild to moderate AD patients.

Methods: A double-blind placebo-controlled study was designed to measure the effect of a year-long course of memantine in patients with a probable AD diagnosis with mild to moderate dementia. The primary outcome measure was stipulated to be change in MRS NAA/Cr ratio in inferior parietal cortex in memantine relative to the placebo treatment condition. The secondary outcome measures were changes in cognitive and function scale scores.

Results: This pilot study failed to demonstrate a benefit of memantine on the primary outcome measure, the inferior parietal NAA/Cr ratio, or the secondary outcome measures.

Conclusions: More studies are needed to determine the effect of memantine on regions of the brain significantly affected by AD pathology.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
MRS scans were performed on a 3 Tesla GE Signa Excite magnet. Voxels were 2×2×2 cm, with centers chosen on a plane 1 cm superior to the plane through the anterior-posterior commissure line, and to include as much gray matter as possible and as little CSF as possible. Three voxels were selected in the Left hemisphere, an inferior parietal voxel, placed as far laterally as possible, behind the sylvian sulcus (shown), an occipital voxel, as posterior as possible, just lateral to the inter-hemispheric sulcus, and a posterior-cingulate voxel, anterior to the occipital cortex and behind the corpus callosum, just lateral to the inter-hemispheric sulcus.

References

    1. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR., Jr MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009;73:287–293. - PMC - PubMed
    1. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology. 1997;203:829–836. - PubMed
    1. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O’Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR., Jr 1H MR spectroscopy incommon dementias. Neurology. 2004;63:1393–1398. - PMC - PubMed
    1. Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br J Radiol. 2007;80(Spec No 2):S146–S152. - PubMed
    1. Kantarci K, Petersen RC, Przybelski SA, Weigand SD, Shiung MM, Whitwell JL, Negash S, Ivnik RJ, Boeve BF, Knopman DS, Smith GE, Jack CR., Jr Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol. 2008;65:1621–1628. - PMC - PubMed

Publication types